745011-75-0

Usage

Uses

Used in Organic Synthesis:
D-Homoserine, N-[(1,1-dimethylethoxy)carbonyl](9CI) is used as a building block for the synthesis of peptides and other complex molecules. Its protective group temporarily blocks the reactivity of certain functional groups, facilitating the synthesis process.
Used in Biochemical Research:
In biochemical research, D-Homoserine, N-[(1,1-dimethylethoxy)carbonyl](9CI) is utilized to study the biosynthesis of methionine and threonine, as well as to investigate the role of homoserine in various biological processes.
Used in Pharmaceutical Development:
D-Homoserine, N-[(1,1-dimethylethoxy)carbonyl](9CI) may have potential applications in the development of pharmaceuticals and other biologically active compounds, given its role as a building block in the synthesis of complex molecules and its potential to be modified for specific therapeutic purposes.
Used in Chemical Compound Protection:
The protective group "N-[(1,1-dimethylethoxy)carbonyl]" in D-Homoserine, N-[(1,1-dimethylethoxy)carbonyl](9CI) is used to temporarily block the reactivity of certain functional groups in organic synthesis, allowing for more controlled and selective reactions to take place.

Upstream product

• 6027-21-0 D-homoserine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 67198-86-1 (R)-2-[(tert-butoxycarbonyl)amino]butano-4-lactone 

Downstream Products

• 258351-86-9 methyl (2R)-2-[(tert-butoxy)carbonylamino]-4-hydroxybutanoate 
• 872983-22-7 (2R)-2-tert-butoxycarbamoyl-4-(tert-butyldiphenylsiloxy)butyric acid 
• 133645-53-1 benzyl (2R)-(tert-butoxycarbonyl)amino-4-hydroxybutanoate 
• 1415236-10-0 tert-butyl (R)-4-hydroxy-1-((4S,5R)-2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxobutan-2-ylcarbamate 
• 872983-24-9 {(1R)-1-[(benzothiazol-2-yl)(hydroxy)methyl]-3-(tert-butyldiphenylsiloxy)propyl}carbamic acid tert-butyl ester 
• 905716-01-0 [3-(tert-butyl-diphenyl-silanyloxy)-1-(methoxy-methyl-carbamoyl)-propyl]-carbamic acid tert-butyl ester 
• 905716-08-7 tert-butyl N-[(1R)-3-[tert-butyl(diphenyl)silyl]oxy-1-formylpropyl]carbamate 

Relevant academic research and scientific papers

Immunomodulators

The invention discloses an immunomodulator, and particularly relates to compounds for inhibiting IL-17A and application of the compounds serving as the immunomodulator in preparation of drugs. The invention discloses an application of the compounds shown as a formula I or a stereoisomer thereof in preparing medicines for inhibiting IL-17A, and provides a new choice for clinically screening and/orpreparing medicines for treating diseases related to IL-17A activity.

DIHYDROPYRIMIDINYLTHIAZOLE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The present invention provides novel compounds having the general formula: wherein R1, R2, X, Y and A are as described herein, compositions including the compounds and methods of using the compounds.

Synthesis of fluorinated analogues of sphingosine-1-phosphate antagonists as potential radiotracers for molecular imaging using positron emission tomography

Sphingosine-1-phosphate (S1P) receptors play major roles in cardiovascular, immunological and neurological diseases. The recent approval of the sphingolipid drug Fingolimod (Gilenya), a sphingosine-1-phosphate agonist for relapsing multiple sclerosis, in 2010 exemplifies the potential for targeting sphingolipids for the treatment of human disorders. Moreover, non-invasive in vivo imaging of S1P receptors that are not available till now would contribute to the understanding of their role in specific pathologies and is therefore of preclinical interest. Based on fluorinated analogues of the S1P1receptor antagonist W146 showing practically equal in vitro potency as the lead structure, the first S1P receptor antagonist [18F]-radiotracer has been synthesized and tested for in vivo imaging of the S1P1receptor using positron emission tomography (PET). Though the tracer is serum stable, initial in vivo images show fast metabolism and subsequent accumulation of free [18F]fluoride in the bones.

Peptide conjugates of 4-aminocyclophosphamide as prodrugs of phosphoramide mustard for selective activation by prostate-specific antigen (PSA)

In our continued effort to develop prodrugs of phosphoramide mustard, conjugates of 4-aminocyclophosphamide (4-NH2-CPA) with three PSA-specific peptides were synthesized and evaluated as substrates of PSA. These include conjugates of cis-(2R,4R)-4-NH2-CPA with a tetrapeptide Succinyl-Ser-Lys-Leu-Gln-OH, a hexapeptide Succinyl-His-Ser-Ser-Lys-Leu-Gln-OH, and a pentapeptide Glutaryl-Hyp-Ala-Ser-Chg-Gln-OH. These conjugates were cleaved by PSA efficiently and exclusively after the expected glutamine residue to release 4-NH2-CPA, the activated prodrug form of phosphoramide mustard. The cleavage was most efficient for the pentapeptide conjugate 3 (Glutaryl-Hyp-Ala-Ser-Chg-Gln-NH-CPA), which showed a half-life of 55 min with PSA, followed by the hexapeptide conjugate 2 (Succinyl-His-Ser-Ser-Lys-Leu-Gln- NH-CPA) and the tertrapeptide conjugate 1 (Succinyl-Ser-Lys-Leu-Gln-NH-CPA) with half-lives of 6.5 and 12 h, respectively. These results indicate a potential of the conjugate 3 as an anticancer prodrug of phosphoramide mustard for selective PSA activation.